ASTRAZENECA Business Summary

AstraZeneca PLC is a research-intensive biopharmaceutical leader that generates revenue primarily through the global sale of proprietary prescription medicines, categorized into three core segments: Oncology, BioPharmaceuticals (encompassing Cardiovascular, Renal, Metabolism, Respiratory, and Immunology), and Rare Disease. In fiscal year 2025, the company achieved $58.7 billion in total revenue, an 8% increase at constant exchange rates, fueled by 16 blockbuster therapies including Tagrisso, Imfinzi, and the Alexion-acquired Soliris franchise. The business model is characterized by high-margin product sales and strategic alliance revenues, with a current focus on a $50 billion U.S. manufacturing expansion and a $15 billion investment in China to secure its 'Ambition 2030' target of $80 billion in annual sales. AstraZeneca competes directly with Merck & Co., Roche, and Pfizer, positioning itself as a top-tier oncology specialist with a uniquely deep penetration in emerging markets and a leading pipeline in antibody-drug conjugates (ADCs) and cell therapies. Formed by the 1999 merger of Astra AB and Zeneca Group, the company is currently spearheaded by CEO Sir Pascal Soriot, who has overseen its strategic pivot toward high-growth biologics since 2012, and CFO Dr. Aradhana Sarin, a medical doctor and former investment banker. Scientific innovation is directed by Dr. Susan Galbraith (EVP, Oncology R&D) and Dr. Sharon Barr (EVP, BioPharmaceuticals R&D), while Rick R. Suarez was appointed in January 2026 to lead the critical U.S. BioPharmaceuticals unit. The Board of Directors, chaired by Michel Demaré, was recently strengthened by the 2025 appointments of Rene Haas (CEO of Arm) and Dr. Karen Knudsen (former CEO of the American Cancer Society), reflecting a strategic emphasis on digital health and clinical oncology expertise. Major institutional shareholders include BlackRock, Vanguard, and Norges Bank Investment Management, underscoring AstraZeneca’s position as the most valuable company on the London Stock Exchange and a primary vehicle for global biopharma growth.